The Complete Guide to Tirzepatide in 2026

Tirzepatide is a dual agonist. It activates two hormone receptors:

• GLP-1: reduces appetite, slows stomach emptying, and helps regulate blood sugar
• GIP: boosts insulin release and appears to enhance GLP-1’s effects

Semaglutide (Ozempic, Wegovy) targets only GLP-1. Tirzepatide’s added GIP activity is believed to explain its stronger weight loss results.

SURMOUNT-1

In SURMOUNT-1, the main tirzepatide obesity trial, adults without diabetes lost an average of:

More than half of participants on the higher doses lost at least 20% of their body weight.

SURMOUNT-5: Tirzepatide vs Semaglutide

In SURMOUNT-5, the first head-to-head obesity trial, tirzepatide produced 20.2% weight loss (about 50 lbs) compared with 13.7% (about 33 lbs) for semaglutide over 72 weeks.

SURPASS-CVOT: Heart Health

SURPASS-CVOT, the largest and longest tirzepatide study to date, followed more than 13,000 adults with type 2 diabetes and heart disease for over 4.5 years. Compared with dulaglutide (Trulicity), tirzepatide showed:

• An 8% lower rate of heart attack, stroke, or cardiovascular death
• A 16% lower rate of death from any cause
• Greater kidney protection

According to the FDA-approved label, tirzepatide is injected once weekly under the skin of the stomach, thigh, or upper arm.

The 2.5 mg starting dose is meant to help your body adjust, not for long-term weight management. Your provider decides your maintenance dose based on results and tolerability.

• Single-dose auto-injector pens
• Single-dose vials (through LillyDirect)
• Zepbound KwikPen: a multi-dose pen holding four weekly doses, approved by the FDA in February 2026

Common Side Effects

The most common tirzepatide side effects are digestive and usually happen during dose increases:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain or discomfort
• Decreased appetite

These often improve over time.

Hair Loss

About 4–5% of people on Zepbound reported hair loss in trials, compared with 1% on placebo. It’s usually temporary and linked to rapid weight loss.

Serious Risks

Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodent studies. It shouldn’t be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Other serious risks listed on the label include:

• Pancreatitis
• Gallbladder problems
• Low blood sugar, especially with insulin or sulfonylureas
• Kidney problems, often from dehydration
• Serious allergic reactions

Birth Control Interaction

Tirzepatide can reduce the effectiveness of oral birth control. The label recommends using a backup method for 4 weeks after starting and after each dose increase.

As of late 2026, LillyDirect self-pay pricing for a 28-day supply is about $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg through 15 mg. Prices and offers can change, so check current pricing.

Retatrutide, Lilly’s investigational triple agonist, has shown greater weight loss in trials but isn’t expected to be FDA-approved before late 2027 or 2028.

• Eat smaller meals and stop when you feel full to reduce nausea.
• Prioritize protein to help preserve muscle during weight loss.
• Stay hydrated, especially if you have GI side effects.
• Include strength training to support lean mass.
• Don’t skip dose increases on your own; follow your provider’s plan.

• What is tirzepatide? A once-weekly dual GLP-1 and GIP agonist, FDA-approved as Mounjaro for type 2 diabetes and Zepbound for weight management and sleep apnea.
• How much weight can you lose on tirzepatide? In SURMOUNT-1, people on 15 mg lost an average of 20.9% of their body weight at 72 weeks.
• Is tirzepatide better than semaglutide? For weight loss, yes. In SURMOUNT-5, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide.
• What’s the difference between Mounjaro and Zepbound? They’re the same compound. Mounjaro is approved for type 2 diabetes, and Zepbound is approved for weight management and sleep apnea.
• How long does it take tirzepatide to work? Many people notice reduced appetite within the first few weeks. Weight loss continues gradually over many months as the dose increases.
• How much does Zepbound cost without insurance? Through LillyDirect, about $299–$449 per month depending on dose, as of late 2026.

• Tirzepatide is a dual GLP-1 and GIP agonist sold as Mounjaro and Zepbound.
• It produced up to 20.9% average weight loss in SURMOUNT-1.
• It outperformed semaglutide head-to-head in SURMOUNT-5.
• Dosing starts at 2.5 mg weekly and increases every 4 weeks.
• New in 2026: the Zepbound KwikPen and lower LillyDirect self-pay pricing.

• Drugs.com – Zepbound FDA Approval History
• Healio – FDA Approves Zepbound KwikPen
• American College of Cardiology – SURMOUNT-1 Trial Summary
• Weill Cornell Medicine – SURMOUNT-5 Head-to-Head Trial
• PharmaTimes – Mounjaro Shows Cardiovascular Benefit in SURPASS-CVOT
• The Rx Index – LillyDirect Zepbound Vial vs Insurance Price
• Ro – Does Zepbound Cause Hair Loss?
• ABC News – Eli Lilly to Sell Zepbound Directly to Consumers